Afyx Therapeutics A/S: Financial statements 2022
CVR: 38793594
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,222,038 and a net result of DKK -7,273,933 compared with DKK -814,180 the year before. Equity in the 2022 report amounted to DKK -1,031,086. The company had 3 employees in the financial year.
- Gross Profit
- DKK -3,222,038
- Profit/Loss
- DKK -7,273,933
- Equity
- DKK -1,031,086
- Total Assets
- DKK 13,406,817
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -3.2M | -7.3M | -1M | 3 |
| 2021 | - | 1.5M | -814K | 6.2M | 2 |
| 2020 | - | -586K | -1.5M | 4.7M | 2 |
| 2019 | - | -1.1M | -1.6M | 1M | 1 |
Official annual report
Keep an eye on Afyx Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Afyx Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 1,509,144, and the net result was DKK -814,180.
About Afyx Therapeutics A/S
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
